Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
IDH1 and IDH2 mutations in gliomas.
- H. Yan, D. Parsons, +15 authors D. D. Bigner
- Biology, Medicine
- The New England journal of medicine
- 10 December 2009
BACKGROUND
A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a… Expand
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
- P. Wen, D. Macdonald, +16 authors S. Chang
- Medicine
- Journal of clinical oncology : official journal…
- 10 April 2010
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance… Expand
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
- J. Vredenburgh, A. Desjardins, +12 authors H. Friedman
- Medicine
- Journal of clinical oncology : official journal…
- 20 October 2007
PURPOSE
The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 3 to 6 months. We performed a phase II trial of bevacizumab, a monoclonal antibody to… Expand
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
- J. Vredenburgh, A. Desjardins, +10 authors H. Friedman
- Medicine
- Clinical Cancer Research
- 15 February 2007
Purpose: Recurrent grade III-IV gliomas have a dismal prognosis with minimal improvements in survival seen following currently available salvage therapy. This study was conducted to determine if the… Expand
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
- J. Sampson, A. Heimberger, +13 authors D. Bigner
- Medicine
- Journal of clinical oncology : official journal…
- 1 November 2010
PURPOSE
Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is a… Expand
Phase II trial of gefitinib in recurrent glioblastoma.
- J. Rich, D. Reardon, +17 authors H. Friedman
- Medicine
- Journal of clinical oncology : official journal…
- 2004
PURPOSE
To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with… Expand
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
- I. Vivanco, H. Robins, +36 authors I. Mellinghoff
- Biology, Medicine
- Cancer discovery
- 1 May 2012
UNLABELLED
Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR kinase… Expand
An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
- J. Sampson, G. Archer, +9 authors D. Bigner
- Medicine
- Molecular Cancer Therapeutics
- 1 October 2009
Conventional therapies for glioblastoma multiforme (GBM) fail to target tumor cells exclusively, such that their efficacy is ultimately limited by nonspecific toxicity. Immunologic targeting of… Expand
Molecularly targeted therapy for malignant glioma
- S. Sathornsumetee, D. Reardon, A. Desjardins, J. Quinn, J. Vredenburgh, J. Rich
- Medicine
- Cancer
- 1 July 2007
Malignant gliomas are relatively uncommon but lethal cancers. Despite recent research efforts in cancer therapy, the prognosis of patients with malignant gliomas has remained dismal. Understanding… Expand
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
- D. Reardon, P. Wen
- Medicine
- The oncologist
- 1 February 2006
Despite advances in standard therapy, including surgical resection followed by radiation and chemotherapy, the prognosis for patients with glioblastoma multiforme (GBM) remains poor. Unfortunately,… Expand